Ultralife Corporation

As of June 30, 2026, Ultralife Corporation carries a market capitalization of 91.65M, placing it among publicly traded companies globally. Its enterprise value stands at 124.94M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Ultralife Corporation's next confirmed earnings release is scheduled for October 22, 2026.

As of June 30, 2026, Ultralife Corporation has 16.66M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.56, and the price-to-book ratio stands at 0.79.

These figures are as of June 30, 2026. The EV/Sales ratio of 0.76 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 124.94M versus a market cap of 91.65M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Ultralife Corporation maintains a current ratio of 2.87, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 33.64, indicating elevated leverage, while an interest coverage ratio of -0.82 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Ultralife Corporation posted a negative return on equity (ROE) of -4.83, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -3.00, reflecting losses generated across the asset base. The company generates approximately 242,352.93 in revenue per employee across its workforce of 676.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.59 indicates how many times Ultralife Corporation sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Ultralife Corporation recorded an income tax benefit of -2.61M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -8.43M and -5.73M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Ultralife Corporation's stock has declined approximately 3.00% over the past 52 weeks. The 50-day moving average sits at 5.49, while the 200-day moving average is 5.48.

Over the twelve months ended June 30, 2026, Ultralife Corporation generated 163.89M in revenue and converted that into -5.73M in net income, yielding earnings per share of -0.35. EBITDA reached -2.59M, while operating income came in at 3.37M.

As of June 30, 2026, Ultralife Corporation holds 5.83M in cash and equivalents against 39.04M in total debt, resulting in a net debt position of 33.21M. Total book value stands at 115.98M, with working capital of 61.10M providing operational flexibility.

Ultralife Corporation produced 4.49M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -2.71M in capital expenditures, free cash flow totaled 1.78M - equivalent to 0.11 per share.

Over the twelve months ended June 30, 2026, Ultralife Corporation posted a gross margin of 24.38, reflecting its pricing power and cost economics. The operating margin of 2.05 and net profit margin of -3.50 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 1.94, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 6.14, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Ultralife Corporation shareholders.

As of June 30, 2026, Ultralife Corporation has an Altman Z-Score of 2.19, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.